知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

56 条记录 (耗时 0.028 秒)

    BISPHOSPHONATE COMPOUNDS
    1.
    发明申请
    BISPHOSPHONATE COMPOUNDS 有权
    二磷酸盐化合物

    公开(公告)号：US20140194389A1

    公开(公告)日：2014-07-10

    申请号：US14205937

    申请日：2014-03-12

    申请人： WARNER CHILCOTT COMPANY, LLC

    发明人： Frank Hallock Ebetino ,  Adam Wieslaw Mazur ,  Roy Lee Martin Dobson

    IPC分类号： C07F9/6574

    CPC分类号： C07F9/65746 ,  C07F9/657181

    摘要： Novel bisphosphonate cyclic acetal compounds are disclosed, as well as methods of preparing the compounds, pharmaceutical compositions including the compounds, and administration of the compounds in methods of treating bone metabolism disorders, such as abnormal calcium and phosphate metabolism.

    摘要翻译： 公开了新的二膦酸酯环状缩醛化合物，以及制备化合物的方法，包括该化合物的药物组合物，以及在治疗骨代谢障碍（例如钙和磷酸钙代谢异常）的方法中给予化合物。

    DOSAGE FORMS OF RISEDRONATE
    3.
    发明申请
    DOSAGE FORMS OF RISEDRONATE 审中-公开
    降血糖剂的剂型

    公开(公告)号：US20100119559A1

    公开(公告)日：2010-05-13

    申请号：US12643321

    申请日：2009-12-21

    申请人： RICHARD JOHN DANSEREAU ,  DAVID ERNEST BURGIO, JR.

    发明人： RICHARD JOHN DANSEREAU ,  DAVID ERNEST BURGIO, JR.

    IPC分类号： A61K31/675 ,  A61K9/00 ,  A61P3/14

    CPC分类号： A61K31/675 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/282 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/2886 ,  A61K9/4891 ,  A61K31/198 ,  A61K31/663 ,  A61K45/06 ,  A61K2300/00

    摘要： Oral dosage forms of a risedronate comprised of a safe and effective amount of a pharmaceutical composition comprising risedronate, a chelating agent, and, means for effecting delayed release of the risedronate and the chelating agent in the small intestine provide immediate release of the pharmaceutical composition to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between risedronate and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of risedronate and the chelating agent to the small intestine, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies.

    摘要翻译： 利塞膦酸盐的安全有效量的药物组合物的口服剂型包含利塞膦酸盐，螯合剂和用于在小肠中实现利塞膦酸盐和螯合剂的延迟释放的方法，使药物组合物立即释放至 哺乳动物受试者的小肠和具有或不具有食物或饮料的二膦酸盐的药学有效吸收。 本发明基本上减轻了利塞膦酸盐和食物或饮料之间的相互作用，其相互作用导致双膦酸盐活性成分不可用于吸收。 因此，所得到的口服剂型可以与或不与食物一起服用。 此外，本发明将利塞膦酸盐和螯合剂递送到小肠，基本上减轻了与双膦酸盐治疗相关的上部GI刺激。 这些益处简化了以前复杂的治疗方案，并可以增加患者对双膦酸盐治疗的依从性。

    Extended estrogen dosing contraceptive regimen
    5.
    发明授权
    Extended estrogen dosing contraceptive regimen 有权
    延长雌激素剂量避孕方案

    公开(公告)号：US07704984B2

    公开(公告)日：2010-04-27

    申请号：US11112290

    申请日：2005-04-22

    申请人： Roger M. Boissonneault

    发明人： Roger M. Boissonneault

    IPC分类号： A61K31/56 ,  A61K31/58

    CPC分类号： A61K31/565 ,  A61K31/567 ,  Y10S514/843 ,  A61K2300/00

    摘要： A method of contraception that provides for sequentially administering to a female of child bearing age: (a) a first composition containing a progestin in an amount equivalent to about 0.3 to about 1.5 mg norethindrone acetate and an estrogen in an amount equivalent to about 5 to about 20 mcg of ethinyl estradiol for about 22 to about 26 days; (b) a second composition containing an estrogen in an amount equivalent to about 5 to about 20 mcg of ethinyl estradiol for about 2 to about 3 days and an optional third composition that is a placebo provided that (i) if estrogen administration is continuous then the first composition is administered for 25 to 26 days, the second composition is administered for 2 to 3 days and no third composition is administered and (ii) if estrogen administration is not continuous then the first composition is administered for 22 to 24 days, the second composition is administered for 2 to 3 days and the third composition is administered for 1 to 4 days. The total cycle length is 28 days, with the first composition administered on day 1 of the menstrual cycle, defined as the first day of menstrual bleeding, or on the first Sunday after the first day of the menstrual cycle.

    摘要翻译： 一种避孕方法，其提供对育龄女性的依次施用：（a）含有相当于约0.3至约1.5mg炔诺酮醋酸酯的量的孕激素的第一组合物和相当于约5至 约20mcg乙炔雌二醇约22至约26天; （b）含有相当于约5至约20mcg乙炔雌二醇的雌激素约2至约3天的第二组合物和任选的第三组合物，其为安慰剂，条件是（i）如果雌激素施用是连续的，则 施用第一组合物25至26天，第二组合物施用2至3天并且不施用第三组合物和（ii）如果雌激素给药不连续，则第一组合物施用22至24天， 施用第二组合物2至3天，第三组合物施用1至4天。 总周期长度为28天，第一组合物在月经周期的第1天施用，定义为月经出血的第一天，或在月经周期的第一天后的第一个星期日。

    Doxycycline metal complex in a solid dosage form
    7.
    发明授权
    Doxycycline metal complex in a solid dosage form 有权

    公开(公告)号：US08415331B2

    公开(公告)日：2013-04-09

    申请号：US12338491

    申请日：2008-12-18

    申请人： Tina deVries ,  Lynn Gold

    发明人： Tina deVries ,  Lynn Gold

    IPC分类号： A61K31/65 ,  A61K9/48 ,  A61K9/20

    CPC分类号： A61K9/1694 ,  A61K9/1688 ,  A61K31/65 ,  Y02A50/401 ,  Y02A50/471

    摘要： The present invention is a solid dosage form of a doxycycline metal complex. The present invention also includes a process for making a doxycycline metal complex in a solid dosage form. The process comprises the steps of (i) providing an aqueous solution of doxycycline or a physiologically acceptable salt thereof; (ii) admixing a metal salt with the aqueous solution; (iii) admixing a base to increase the pH of the aqueous solution, thereby forming a suspension of doxycycline metal; and (iv) drying the suspension, thereby forming a dry granulation of doxycycline metal complex.

    Compositions for reducing the incidence of drug induced arrhythmia
    9.
    发明授权
    Compositions for reducing the incidence of drug induced arrhythmia 有权
    用于降低药物诱导性心律失常发生率的组合物

    公开(公告)号：US08183284B2

    公开(公告)日：2012-05-22

    申请号：US11489756

    申请日：2006-07-20

    申请人： Joseph Michael Sprafka, II ,  Jose Mauro Goulart-Brum

    发明人： Joseph Michael Sprafka, II ,  Jose Mauro Goulart-Brum

    IPC分类号： A01N43/08 ,  A61K31/34

    CPC分类号： A61K31/496 ,  A61K31/22 ,  A61K31/366 ,  A61K31/401 ,  A61K31/60 ,  A61K31/616 ,  A61K45/06 ,  A61K2300/00

    摘要： In accordance with the present invention, novel methods and formulations are provided for treating and preventing the incidence of drug-induced pro-arrhythmia, including torsades de pointes. The methods and formulations comprise a combination of a drug that induces torsade de pointes, such as Class III antiarrhythmics, certain antimicrobials, antihistamines, antidepressants, antipsychotics, diuretics, with an aspirin and/or a statin. In certain embodiments, the compositions and methods for treatment comprise azimilide and aspirin and/or a statin. These compositions may be administered by different routes, including orally. In certain embodiments where the antiarrhythmic is azimilide it may be administered orally in a dose of about 25 mg to about 300 mg.

    摘要翻译： 根据本发明，提供了用于治疗和预防药物诱导的心律失常（包括尖端扭转型室性心律失常）发生的新方法和制剂。 方法和制剂包括诱导尖端扭转型室性心脏病的药物，例如III类抗心律失常药，某些抗微生物剂，抗组胺药，抗抑郁药，抗精神病药，利尿剂与阿司匹林和/或他汀类药物的组合。 在某些实施方案中，治疗的组合物和方法包括阿齐利特和阿司匹林和/或他汀类。 这些组合物可以通过不同途径施用，包括口服给药。 在其中抗心律失常药是阿立米IL的某些实施方案中，其可以以约25mg至约300mg的剂量口服给药。

    COMPOSITIONS OF AZIMILIDE DIHYDROCHLORIDE
    10.
    发明申请
    COMPOSITIONS OF AZIMILIDE DIHYDROCHLORIDE 审中-公开
    二酰亚胺二氯化物的组合物

    公开(公告)号：US20110237603A1

    公开(公告)日：2011-09-29

    申请号：US13156810

    申请日：2011-06-09

    申请人： Nancy Lee REDMAN-FUREY

    发明人： Nancy Lee REDMAN-FUREY

    IPC分类号： A61K31/496 ,  A61P9/06

    CPC分类号： C07D405/12

    摘要： The present invention is directed to solvates and various polymorphic forms of (E)-1-[[[5-(4-chlorophenyl)-2-furanyl]methylene]amino]-3-[4-(4-methyl-1-piperazinyl)butyl]-2,4-imidazolidinedione dihydrochloride and pharmaceutical compositions thereof.

    摘要翻译： 本发明涉及（E）-1 - [[[5-（4-氯苯基）-2-呋喃基]亚甲基]氨基] -3- [4-（4-甲基-1- 哌嗪基）丁基] -2,4-咪唑烷二酮二盐酸盐及其药物组合物。